Protara Therapeutics
TARA
31 hedge funds and large institutions have $14.6M invested in Protara Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 2 closing their positions.
100% more call options, than puts
Call options by funds: $4K | Put options by funds: $2K
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0% more funds holding
Funds holding: 31 → 31 (0)
2% less capital invested
Capital invested by funds: $14.9M → $14.6M (-$308K)
1.64% less ownership
Funds ownership: 50.25% → 48.61% (-1.6%)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$267K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.5K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.32K |
| 4 |
BlackRock
New York
|
+$2.71K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$707 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$678K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$491K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$130K |
| 4 |
Millennium Management
New York
|
-$65K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$48.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $268 | +$316 | +100 | New |
|
27
Morgan Stanley
New York
| $67 | -$691 | -219 | -90% |
|
28
Bank of America
Charlotte,
North Carolina
| $58 | +$69 | +22 | New |
|
|
29
Dimensional Fund Advisors
Austin,
Texas
| $45 | +$3.32K | +1,052 | +7% |
|
|
VF
30
Virtu Financial
New York
| – | -$37K | -12,465 | Closed |
|
|
FAIM
31
Financial Advocates Investment Management
Olympia,
Washington
| – | -$678K | -6,187 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | +$420 | +133 | New |
|
TARA Hedge Fund Activity: Q4 2022 in Review
31 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2022, worth a combined $14.6M — down 2.1% from $14.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TARA positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 10 trimmed.
The largest buyer was Privium Fund Management (UK), adding an estimated $267K. The largest seller was Financial Advocates Investment Management, exiting entirely with an estimated $678K sold.
- 31 institutional investors held Protara Therapeutics (TARA) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $14.6M of Protara Therapeutics stock for Q4 2022, down 2.1% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q4 2022 and 2 closed out, a net change of +1 holder.
- The largest Protara Therapeutics buyer in Q4 2022 was Privium Fund Management (UK), an estimated $267K added.
- The largest Protara Therapeutics seller in Q4 2022 was Financial Advocates Investment Management, an estimated $678K sold.
Based on aggregated 13F filings for Q4 2022.